ReviewTherapeutic advances in medical oncology2023

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.

Hiromi Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.